Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 159-164

  Bhutani, Divaya ^a   Dyson, Gregory ^a,b   Manasa, Richard ^a   Deol, Abhinav ^a   Ratanatharathorn, Voravit ^a   Ayash, Lois ^a   Abidi, Muneer ^a   Lum, Lawrence G ^a   Al Kadhimi, Zaid ^c   Uberti, Joseph P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Allogeneic stem cell transplantation; Cytomegalovirus gastroenteritis; Cytomegalovirus viremia; Graft versus host disease

Indexed keywords

GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; VIRUS ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL GRAFT VERSUS HOST DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VIREMIA; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BLOOD; CHRONIC DISEASE; CYTOMEGALOVIRUS INFECTIONS; DONOR; GASTROINTESTINAL TRACT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; PROCEDURES; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GASTROENTERITIS; GASTROINTESTINAL TRACT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84927155302     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.004     Document Type: Article

References (23)

1. Bowden R.A., Sayers M., Flournoy N., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. NEngl J Med 1986, 314:1006-1010.
2. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. JInfect Dis 1986, 153:478-488.
3. Miller W.J., McCullough J., Balfour H.H., et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991, 7:227-234.
4. Winston D.J., Ho W.G., Lin C.H., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987, 106:12-18.
5. Meyers J.D., Reed E.C., Shepp D.H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. NEngl J Med 1988, 318:70-75.
6. Schmidt G.M., Kovacs A., Zaia J.A., et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988, 46:905-907.
7. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. NEngl J Med 1991, 325:1601-1607.
8. Mori T., Mori S., Kanda Y., et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 33:431-434.
9. Couriel D., Caldera H., Champlin R., Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101:1936-1946.
10. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
11. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
12. Cho B.S., Yahng S.A., Kim J.H., et al. Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. Ann Hematol 2013, 92:497-504.
13. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
14. Martin P.J., Schoch G., Fisher L., et al. Aretrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
15. Mori T., Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol 2010, 91:588-595.
16. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
17. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. JInfect Dis 2002, 185:273-282.
18. Liu Y.C., Lu P.L., Hsiao H.H., et al. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann Hematol 2012, 91:587-595.
19. Wingard J.R., Chen D.Y., Burns W.H., et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988, 71:1432-1437.
20. Qamruddin A.O., Oppenheim B.A., Guiver M., et al. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001, 27:301-306.
21. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
22. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
23. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.